Title: 246P Palbociclib dose patterns in Swedish patients with metastatic breast cancer: Evidence from the SIRI study
Abstract: Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor indicated for use in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). The Swedish Ibrance Registries Insights (SIRI) study investigated real-world dose patterns using a nationwide Swedish cohort of palbociclib-treated MBC patients.